What is Panfor SR used for?

Panfor SR is indicated to control blood sugar in people with type 2 diabetes. Use of the drug may experience unwanted side effects. Therefore, patients need to take the drug under the advice and prescription of the doctor.

Metformin hydrochloride in Panfor is considered an anti-hyperglycemic agent, helping to improve glucose tolerance in people with type 2 diabetes. In addition, this ingredient also helps to reduce plasma glucose levels even after eating. Metformin hydrochloride's mechanism of action is not the same as that of the sulfonylurea group and may act in the body through the following 3 mechanisms:
Metformin hydrochloride can reduce glucose production in the liver by inhibiting jaw neoplasia. glucose levels and glycogenolysis; The compound increases peripheral glucose uptake in muscle by increasing insulin sensitivity; Compound that slows intestinal glucose absorption Metformin hydrochloride compound did not cause hypoglycaemia in patients without diabetes or hyperinsulinemia. During treatment with Panfor SR, insulin secretion remains normal while fasting insulin and daily plasma insulin levels may decrease, respectively.
After oral administration, the compound Metformin in the drug may be in a delayed-release form, reaching peak blood concentrations after 7 hours and the time to reach this concentration can be from 4 to 8 hours. With repeated administration of the delayed-release formulation, Metformin compounds do not accumulate in plasma.
Panfor drugs include the following:
Panfor SR 500; Drug Panfor SR 750 ; Panfor SR 1000 medicine. After using the drug at the usual dose with normal Metformin content 750, the volume of distribution reached 654 +/-358L. Metformin hydrochloride compounds have almost no binding to plasma proteins. At usual therapeutic doses, Metformin hydrochloride reaches steady-state plasma concentrations after 24 to 48 hours with values ​​less than 1 mg/ml.
Metabolism and elimination of Panfor drug during treatment. Metformin hydrochloride compounds are eliminated almost exclusively in the urine and do not appear to be metabolized by the liver or may be excreted in the bile. Renal clearance can be approximately 3.5 times that of creatinine, so tubular secretion is the major route of elimination for Metformin hydrochloride. Following administration, approximately 90% of the absorbed drug is excreted by the kidneys within the first 24 hours and the plasma half-life is about 17.6 hours.

Dosage of Panfor SR should be determined for each patient as well as depending on the level of tolerance and effect of the drug during treatment. Dosage should not exceed the maximum recommended dose of 2000mg/day. With the course of treatment using Panfor SR, it is recommended to start with a low dose and then slowly increase it to reduce the side effects of the drug on the gastrointestinal tract.
When starting treatment with Panfor SR and in the process of determining the appropriate dose, the patient should have a blood sugar test at that time to assess the response of the drug to the treatment course. After that, the patient should also be assigned a glycosylated hemoglobin test every 3 months.
The aim of treatment with Panfor SR is to reduce fasting blood sugar and glycosylated hemoglobin values ​​to normal or near normal values. Furthermore, patients can be treated with short-term medication during the period of glycemic control along with diet.
The starting dose of Panfor SR is usually 500mg once a day in the evening. The drug should be increased in dose only up to a maximum of 2000mg/day and about 500mg per week. In case the patient does not achieve glycemic control with the maximum dose of 2000mg/day, it is advisable to discuss with the doctor to determine the appropriate dose.
In case a person with diabetes is planning to switch to a medication for the treatment of the disease, it is necessary to stop using the drug and consult a doctor. However, if Panfor SR is used in combination with insulin, better blood sugar control can be achieved.
Although Panfor SR is effective in the treatment of diabetes, the above data is for reference only. Therefore, patients should consult a doctor before using this medicine and use it as prescribed.

Treatment of non-insulin dependent diabetes with Panfor SR may be contraindicated in some cases such as:
People with hypersensitivity to the drug's components or with acute catabolism, infection; Cases of acute/chronic metabolic acidosis; Cases of decreased and dysfunctional kidney function; Have severe respiratory disease with hypoxemia; Severe liver disease... In addition, in a few cases of using Panfor SR, unwanted side effects may occur such as:
Frequent side effects: Nausea, diarrhea or abdominal pain, loss of feeling appetite...; Rare side effects: Lactic acidosis, decreased absorption of vitamin B12, leading to a decrease in serum concentrations during prolonged treatment with Panfor SR. Therefore, it is necessary to consider before using the drug in cases of patients presenting with megaloblastic anemia. Other rare undesirable effects: Erythema, pruritus or urticaria, liver dysfunction.

Using Panfor SR with Metformin ingredient requires regular monitoring of laboratory tests along with blood glucose measurement results to determine the minimum effective dose of Metformin. Patients during treatment still need to be advised to adjust their diet appropriately. Because therapeutic nutrition is seen as an important role in diabetes management.
Metformin component is not suitable in case of treatment for the elderly or with signs of impaired renal function. Therefore, when starting treatment with Panfor SR, serum creatinine should be checked.
If during surgery, the patient should stop using Metformin about 48 hours before. The drug should only be used again after 48 hours of intervention or the possibility of oral ingestion.
In summary, Panfor SR has the effect of supporting the treatment of patients with diabetes. Patients need to use the drug exactly as prescribed by the doctor to increase the effectiveness of treatment and ensure safety for health.